Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Medtronic
McKesson
Merck

Last Updated: May 27, 2022

Investigational Drug Information for Rilotumumab


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Rilotumumab?

Rilotumumab is an investigational drug.

There have been 11 clinical trials for Rilotumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2014.

The most common disease conditions in clinical trials are Stomach Neoplasms, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Southwest Oncology Group.

There are fourteen US patents protecting this investigational drug and two hundred and sixty-six international patents.

Recent Clinical Trials for Rilotumumab
TitleSponsorPhase
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric CancerAmgenPhase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNational Cancer Institute (NCI)
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerSouthwest Oncology Group

See all Rilotumumab clinical trials

Clinical Trial Summary for Rilotumumab

Top disease conditions for Rilotumumab
Top clinical trial sponsors for Rilotumumab

See all Rilotumumab clinical trials

US Patents for Rilotumumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rilotumumab See Plans and Pricing Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL) See Plans and Pricing
Rilotumumab See Plans and Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) See Plans and Pricing
Rilotumumab See Plans and Pricing Cancer treatment with c-met antagonists and correlation of the latter with HGF expression Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
Rilotumumab See Plans and Pricing Method for predicting efficacy of c-Met inhibitor SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) See Plans and Pricing
Rilotumumab See Plans and Pricing Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) See Plans and Pricing
Rilotumumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rilotumumab

Drugname Country Document Number Estimated Expiration Related US Patent
Rilotumumab Canada CA2900764 2033-02-08 See Plans and Pricing
Rilotumumab European Patent Office EP2954056 2033-02-08 See Plans and Pricing
Rilotumumab Hong Kong HK1218930 2033-02-08 See Plans and Pricing
Rilotumumab Japan JP2016509014 2033-02-08 See Plans and Pricing
Rilotumumab World Intellectual Property Organization (WIPO) WO2014124326 2033-02-08 See Plans and Pricing
Rilotumumab Australia AU2013220749 2032-02-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Medtronic
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.